• A case of rare splice-site Bruton's tyrosine kinase mutation with atypical X-linked agammaglobulinemia
• A deep intronic BTK variant underlies X-linked agammaglobulinemia
• A novel mutation in SLC39A7 identified in a patient with autosomal recessive agammaglobulinemia: The impact of the J Project
• A Registry Study of 240 Patients with X-Linked Agammaglobulinemia Living in the USA
• An International Survey of Allogeneic Hematopoietic Cell Transplantation for X-Linked Agammaglobulinemia
• An X-linked agammaglobulinemia (XLA) patient with fever and disturbance of consciousness: infection with Torque teno virus?
• B cell repertoire in patients with a novel BTK mutation: expanding the spectrum of atypical X-linked agammaglobulinemia
• BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells
• Campylobacter jejuni Pericarditis: A Case Report
• Case report of renal manifestations in X-linked agammaglobulinemia
• Case report: Evolution of pulmonary manifestations and virological markers in critical COVID-19 infection in Bruton's agammaglobulinemia
• CD38-mediated Inhibition of Bruton's Tyrosine Kinase in Macrophages Prevents Endotoxemic Lung Injury
• Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies
• Chronic immune thrombocytopenia in a child with X-linked agammaglobulinemia-an uncommon phenotype
• Circulating bioactive bacterial DNA is associated with immune activation and complications in common variable immunodeficiency
• Clinical and genetic findings in two siblings with X-Linked agammaglobulinemia and bronchiolitis obliterans: a case report
• Clinical and laboratory observation on immunoglobulin replacement therapy switching from an intravenous to a subcutaneous route in a Malaysian X-linked agammaglobulinemia patient
• Clinical features and mutational analysis of X-linked agammaglobulinemia patients in Malaysia
• Clinical Utility of Flow-Cytometry for Diagnosis and Genotype Phenotype Correlation in a Cohort of X-linked Agammaglobulinemia Patients
• Clinical, immunological and genomic characteristics of children with X-linked agammaglobulinemia from Kerala, South India
• Combined Treatment of Progressive Encephalitis in an X-linked Agammaglobulinemia Patient
• Contribution of B cells to cortical damage in multiple sclerosis
• Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia
• COVID-19 and X-linked agammaglobulinemia (XLA) - insights from a monogenic antibody deficiency
• COVID-19 Pneumonia with Migratory Pattern in Agammaglobulinemic Patients: A Report of Two Cases and Review of Literature
• Cytomegalovirus Pneumonia in a Patient with X-Linked Agammaglobulinemia: A Case Report
• Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL
• Discordant Phenotypes of Nephritis in Patients with X-linked Agammaglobulinemia
• Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase
• Discovery of novel BTK PROTACs for B-Cell lymphomas
• Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy
• Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?
• Ecthyma gangrenosum as a presenting feature of X-linked agammaglobulinemia: A case study
• Enhanced IFN Sensing by Aggressive Chronic Lymphocytic Leukemia Cells
• Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia
• Exposure to Therapeutic BTK Inhibitors Induces Phenocopying of <em>Btk29A</em> Mutants in the Fruit Fly <em>Drosophila melanogaster</em>
• Fenebrutinib in H₁ antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
• Follow-up of immune response in patients with common variable immunodeficiency following SARS-CoV-2 vaccination
• Frontline treatment in CLL: the case for time-limited treatment
• Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia
• Genetic study of an X-linked agammaglobulinemia pedigree caused by an BTK mutation
• Health-Related Quality of Life in 91 Patients with X-Linked Agammaglobulinemia
• Hematopoietic stem cell gene editing rescues B-cell development in X-linked agammaglobulinemia
• Hemizygous BTK Gene Variant Causing X-Linked Agammaglobulinemia in Two Siblings
• Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors 
• Identification of four novel mutations in BTK from six Chinese families with X-linked agammaglobulinemia
• IgA nephropathy in a child with X-linked agammaglobulinemia: a case report
• Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
• Immunologic Control of Disseminated Aichi Virus Infection in X-Linked Agammaglobulinemia by Transplantation of TcRαβ-Depleted Haploidentical Hematopoietic Cells
• Improved HUMARA for the Detection of X-Linked Agammaglobulinemia Carriers
• Infections With Enterohepatic Non-<em>H. pylori Helicobacter</em> Species in X-Linked Agammaglobulinemia: Clinical Cases and Review of the Literature
• Inhibition of Serum- and Glucocorticoid-Regulated Protein Kinase-1 Aggravates Imiquimod-Induced Psoriatic Dermatitis and Enhances Proinflammatory Cytokine Expression through the NF-kB Pathway
• Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry
• Investigation of a synonymous mutation in Btk in a patient with agammaglobulinemia: A case report
• Keratoconjunctivitis as a Single Entity in X-linked Agammaglobulinemia?
• Kinomics platform using GBM tissue identifies BTK as being associated with higher patient survival
• Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients
• Macrolide/fluoroquinolone-resistant Campylobacter jejuni-induced cellulitis in a patient with X-linked agammaglobulinaemia successfully treated with carbapenem
• Managing Waldenström's macroglobulinemia with BTK inhibitors
• MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)
• Membranoproliferative Glomerulonephritis Type I Associated with Intravenous Immunoglobulin Administration Arising in a Child with X-Linked Agammaglobulinemia: A Case Report and a Reappraisal
• Molecular pathogenesis and treatment of chronic lymphocytic leukemia
• Monoclonal Antibodies for COVID-19 in X-linked Agammaglobulinemia: a Case Series
• Naïve Regulatory T Cell Subset Is Altered in X-Linked Agammaglobulinemia
• Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant
• Nodular Skin Lesions in a Patient With X-Linked Agammaglobulinemia
• Non-Helicobacter pylori Helicobacter Species as a Cause of Refractory Chronic Cellulitis in X-Linked Agammaglobulinemia
• NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts
• Obturator internus muscle abscess in a case of X-linked agammaglobulinemia
• Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models
• Outcomes among racial and ethnic minority groups with X-linked agammaglobulinemia from the USIDNET registry
• Peripheral B Cell Deficiency and Predisposition to Viral Infections: The Paradigm of Immune Deficiencies
• Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia
• Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
• Pulmonary Computed Tomography Screening Frequency in Primary Antibody Deficiency
• Pulmonary Radiological Manifestations of Humoral and Combined Immunodeficiencies in a Tertiary Pediatric Center
• Rare deleterious mutations in Bruton's tyrosine kinase as biomarkers for ibrutinib-based therapy: an in silico insight
• Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure-activity relationship
• Relapsing <em>Helicobacter cinaedi</em> Cellulitis without Bacteremia in a Patient with X-linked Agammaglobulinemia after 1 Year of Antibiotic Prophylaxis
• Response to mRNA COVID-19 vaccination in three XLA patients
• Responses to SARS-CoV-2 Vaccines of Patients with Common Variable Immune Deficiencies and X-linked Agammaglobulinemia
• Retrospective study of 98 patients with X-linked agammaglobulinemia complicated with arthritis
• Safety and efficacy of biologic immunosuppressive treatment in juvenile idiopathic arthritis associated with inborn errors of immunity
• SARS-CoV-2 infection in a X-linked agammaglobulinemia adolescent: An immunological approach to treatment
• SARS-CoV-2 Infection in an Adolescent With X-linked Agammaglobulinemia
• SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients
• Severe Tick-Borne Encephalitis (TBE) in a Patient with X-Linked Agammaglobulinemia; Treatment with TBE Virus IgG Positive Plasma, Clinical Outcome and T Cell Responses
• Skin abscesses, X-linked agammaglobulinaemia and spastic paraplegias in a male patient
• Successful dupilumab therapy for atopic dermatitis in a patient with X-linked agammaglobulinaemia
• Successful treatment of atopic dermatitis with dupilumab in the setting of X-linked agammaglobulinemia
• Successful use of dupilumab to treat eczema in a child with X-linked agammaglobulinemia
• Susceptibility to Cryptococcus neoformans Infection with Bruton's Tyrosine Kinase Inhibition
• T Cell Abnormalities in X-Linked Agammaglobulinaemia: an Updated Review
• Two-Track Virtual Screening Approach to Identify the Dual Inhibitors of Wild Type and C481S Mutant of Bruton's Tyrosine Kinase
• Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase
• Viral infections and inborn errors of immunity
• X-Linked Agammaglobulinemia and COVID-19: Two Case Reports and Review of Literature
• X-linked Agammaglobulinemia Diagnosed Following Bezold's Abscess: A Case Report
• X-Linked Agammaglobulinemia with Kawasaki Disease
• X-Linked Agammaglobulinemia: Infection Frequency and Infection-Related Mortality in the USIDNET Registry